FDA May Ease Up On CV Safety Requirements For GI Motility Drugs Compared To Diabetes, Obesity

Developers of 5-HT4 agonists should not be required to conduct dedicated cardiovascular studies, despite the safety concerns raised by two previously approved products in the class, an FDA advisory committee said.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America